

Date of preparation: 2022-11-23

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Extension of cooperation with Novavax, Inc.

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 on the conclusion, with Novavax, Inc. (“Novavax”), a commercial contract manufacturing agreement (“Manufacturing Agreement”), and subsequent current reports on the broadening and extension of the collaboration with Novavax, the Management Board of Mabion S.A. (“Company”) hereby informs that on 23 November 2022, it signed a further extension of the services of the Manufacturing Agreement with Novavax, in the form of Statement of Work (“SOW#9”).

The scope of SOW#9 involves the Company's tasks consisting in conducting peptide mapping analysis for the active substance (DS) as well as the finished product (DP) of rS SARS-CoV-2 protein samples of Novavax products – both Wuhan and Omicron variants. The contracted tasks involve a method feasibility study, method validation and regular testing of samples produced at Mabion and other entities providing manufacturing services to Novavax. If required by Novavax, routine testing of samples will be carried out in a GMP (Good Manufacturing Practice) compliant environment.

The first stage of the work will consist of implementing the peptide mapping method. Next, regular analyses of the commissioned samples will be performed (within 1 month of the delivery of a given sample), ending with the issuance of an appropriate certificate. The remuneration for the work on the implementation of the method, which constitutes the first stage of the order, will amount to more than USD 500 thousand, while the total value of SOW#9 will depend on the next stage of the order, namely the number of regular analyses carried out by the Company in each reporting period.